H
Hiromi Takeda
Researcher at University of Connecticut Health Center
Publications - 4
Citations - 659
Hiromi Takeda is an academic researcher from University of Connecticut Health Center. The author has contributed to research in topics: Erythropoietin & Erythropoiesis. The author has an hindex of 4, co-authored 4 publications receiving 619 citations.
Papers
More filters
Journal ArticleDOI
Placental but not heart defects are associated with elevated hypoxia-inducible factor α levels in mice lacking prolyl hydroxylase domain protein 2
TL;DR: The disrupted Phd genes indicate that among all three PHD proteins, PHD2 is uniquely essential during mouse embryogenesis.
Journal ArticleDOI
Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins
Kotaro Takeda,Hector L. Aguila,Nehal S. Parikh,Xiping Li,Katie Lamothe,Li-Juan Duan,Hiromi Takeda,Frank S. Lee,Guo-Hua Fong +8 more
TL;DR: This work shows that different PHD isoforms differentially regulate HIF-alpha stability in the adult liver and kidney and suppress Epo expression and erythropoiesis through distinct mechanisms, and suggests that PHD1/3 double deficiency leads to erythrocytosis partly by activating the hepatic Hif-2alpha/Epo pathway, whereas PHD2 deficiency leads through activating the renal Epo pathway.
Journal Article
Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Commentary
Eric Metzen,Kotaro Takeda,Hector L. Aguila,Nehal S. Parikh,Xiping Li,Katie Lamothe,Li-Juan Duan,Hiromi Takeda,Frank S. Lee,Guo-Hua Fong +9 more
TL;DR: In this article, different PHD isoforms differentially regulate HIF-α stability in the adult liver and kidney and suppress Epo expression and erythropoiesis through distinct mechanisms.
Journal ArticleDOI
Improved Vascular Survival and Growth in the Mouse Model of Hindlimb Ischemia by a Remote Signaling Mechanism
TL;DR: The data indicate that vascular survival and growth in ischemia-injured tissue may be stimulated by suppressing PHD2 in a remotely located tissue and may provide highly effective angiogenesis therapies without the need for directly accessing target tissues.